Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Filters applied: . Clear all
Page 1
Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.
Jalal S, Waterhouse D, Edelman MJ, Nattam S, Ansari R, Koneru K, Clark R, Richards A, Wu J, Yu M, Bottema B, White A, Hanna N. Jalal S, et al. Among authors: hanna n. J Thorac Oncol. 2009 Nov;4(11):1420-4. doi: 10.1097/JTO.0b013e3181b624ae. J Thorac Oncol. 2009. PMID: 19701110 Free article. Clinical Trial.
PURPOSE: Pemetrexed is a standard treatment against recurrent non-small cell lung cancer (NSCLC), and cetuximab has single-agent activity against NSCLC. ...PATIENTS AND METHODS: Patients with recurrent NSCLC and an Eastern Cooperat …
PURPOSE: Pemetrexed is a standard treatment against recurrent non-small cell lung cancer (NSCLC), and cet …
Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.
Jalal S, Ansari R, Govindan R, Bhatia S, Bruetman D, Fisher W, Masters G, White A, Stover D, Yu M, Hanna N; Hoosier Oncology Group. Jalal S, et al. Among authors: hanna n. J Thorac Oncol. 2009 Jan;4(1):93-6. doi: 10.1097/JTO.0b013e31818de1e6. J Thorac Oncol. 2009. PMID: 19096313 Free article. Clinical Trial.
INTRODUCTION: : Small cell lung cancer (SCLC) is initially a chemotherapy-sensitive disease. Nevertheless, drug-resistance results in disease recurrence in most patients. ...Based on the need to discover better systemic therapies, we cond …
INTRODUCTION: : Small cell lung cancer (SCLC) is initially a chemotherapy-sensitive disease. Nevertheless, drug- …